Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05667285Terminated

BIOFLOW-china Post-marketing Study (BIOTRONIK)

Role: lead

NCT04390841Not ApplicableCompleted

Qubic Stim Cardiac Stimulator in China

Role: lead

NCT02870985Not ApplicableCompleted

BIOTRONIK Orsiro Pre-Marketing Registration

Role: lead

NCT02912715Not ApplicableCompleted

BIOLUX P-IV CHINA ( BIOTRONIK )

Role: lead

NCT02380300Completed

Registry Study of Clinical Application of MRI Compatible CIED

Role: lead

All 5 trials loaded